针对女性低活性性欲障碍的全身丸激素治疗的特点 - - 索赔数据库分析
Pranjal Agrawal1, Yeonsoo Sara Lee2, Aurora J Grutman1
1Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States.
The journal of sexual medicine
|March 5, 2024
概括
疗法 (TTh) 对具有低活性性欲障碍 (HSDD) 的女性显示增加但变化的处方率. 需要进一步的研究来确定最佳和安全的TTh用于女性性功能障碍的使用.
科学领域:
- 内分泌学 在内分泌学.
- 妇女健康 妇女健康
- 药理学 药理学是指药理学的学科.
背景情况:
- 建议在绝经后的女性中使用激素治疗 (TTh) 治疗低活性的性欲障碍 (HSDD).
- 目前没有足够的数据支持在经期前经历性功能障碍的女性中使用TTh.
研究的目的:
- 评估诊断为HSDD的妇女的TTh的处方趋势.
- 分析TTh.Th.的使用途径和与雌激素的同时使用.
主要方法:
- 使用来自TriNetX钻石网络的电子健康记录进行了队列分析.
- 该研究包括18至70岁的女性,她们被诊断患有HSDD.
- 分析了处方趋势,服用途径和雌激素的联合使用.
主要成果:
- 虽然HSDD的TTh处方增加了,但观察到治疗持续时间,服用途径和雌激素联合使用的显著变化.
- 在33418名患有HSDD的女性中,2.54%接受了丸激素处方,趋势自2015年以来呈现线性增长,特别是在41-55岁年龄组.
- 尽管处方率上升,的处方不足仍然是一个问题.
结论:
- 对于HSDD妇女的TTh最佳和长期使用,需要进一步研究.
- 对于患有HSDD的绝经前妇女,应考虑TTh,等待对疗效和安全性的进一步研究.
- 解决HSDD管理中的差异需要更多的研究,以确保安全有效的治疗机会.
相关概念视频
Testosterone: Functions and Regulation
648
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
648
Menopause
158
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
158
Signs of Puberty
347
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
347
Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
Antidepressant Drugs: MAOIs and Other Agents
229
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
229
Disorders of the Female Reproductive System
358
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
358


